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Objective. To use coronary revascularization choice to illustrate the application of a
method simulating a treatment’s effect on subsequent resource use.
Data Sources. Medicare inpatient and outpatient claims from 2002 to 2008 for
patients receiving multivessel revascularization for symptomatic coronary disease in
2003–2004.
Study Design. This retrospective cohort study of 102,877 beneficiaries assessed sur-
vival, days in institutional settings, and Medicare payments for up to 6 years following
receipt of percutaneous coronary intervention (PCI) or coronary artery bypass grafting
(CABG).
Methods. A three-part estimator designed to provide robust estimates of a treatment’s
effect in the setting of mortality and censored follow-up was used. The estimator
decomposes the treatment effect into effects attributable to survival differences versus
treatment-related intensity of resource use.
Principal Findings. After adjustment, on average CABG recipients survived 23 days
longer, spent an 11 additional days in institutional settings, and had cumulative Medi-
care payments that were $12,834 higher than PCI recipients. The majority of the differ-
ences in institutional days and payments were due to intensity rather than survival
effects.
Conclusions. In this example, the survival benefit from CABG was modest and the
resource implications were substantial, although further adjustments for treatment
selection are needed.
Key Words. Censoring, comparative effectiveness research, coronary artery
bypass grafting, percutaneous coronary intervention
Measurement of the long-term impact of medical treatments on resource utili-
zation is essential to health technology assessment. Whether such measure-
ment is performed using a randomized trial or observational study, most
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cohorts include some patients who were alive at the end of their data availabil-
ity but whose resource use was not measured for the entire period of interest;
these patients are said to be censored at the point from which subsequent
resource use is unknown. Even when censoring occurs at random, conven-
tional survival analysis methods produce biased cost estimates due to hetero-
geneity in cost trajectories (Lin et al. 1997).
Previous methods to address the issue of estimating resource use with
censored data have notable limitations. Early approaches using survival-
adjusted models were shown to produce biased estimates when death and
censoring occurred continuously during the study period, rather than at
predictable, discrete intervals such as every 30 days (Lin et al. 1997). Inverse
probability weighting (IPW) approaches solve this limitation (Bang and Tsiatis
2000; Lin 2000), but they do not allow decomposition of a treatment’s effect
on resource use into an effect due to the treatment altering how long a patient
lives (the survival effect) and an effect due to the treatment altering how many
resources a surviving patient consumes (the intensity effect) (Basu and Manning
2010). Such decomposition, which is possible with survival-adjusted method-
ologies, is of interest in health technology assessment because it allows for
more detailed examination of how treatments affect long-term costs of care.
An extreme example of a treatment affecting both survival and resource
use is highly active antiretroviral therapy (HAART) for human immunodefi-
ciency virus infection. HAART dramatically improves survival, meaning a
substantial survival effect due to prolonged life spans among patients receiv-
ing HAART is likely. In addition, there is also an important intensity effect
associated with HAARTusage, consisting of increased costs for antiretroviral
medications, but lower costs due to prevention of opportunistic infections.
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However, most cost analyses of HAART have not considered potential sur-
vival effects (Schackman et al. 2006). Although most cost-effectiveness analy-
ses do not consider survival effect-induced costs (Gold et al. 1996), failing to
incorporate these effects may bias them in favor of therapies that extend life
span versus therapies that improve quality of life (Meltzer 1997). Furthermore,
if an analytic objective is to forecast long-term expenditures for a third-party
payer, incorporation of survival effect-induced costs is essential.
A recently developed approach extends the survival-adjusted methodol-
ogy to produce consistent estimates for resource use, even when censoring
and death occur continuously throughout the follow-up period. The approach
also preserves the ability to decompose differences in resource use into sur-
vival and intensity effects (Basu and Manning 2010). In addition to these
advantages, the authors identify an additional important and poorly appreci-
ated limitation of IPWmethods: the potential for considerable bias when IPW
estimators are used to evaluate the costs of treatments that have both intensity
and survival effects, as well as substantial precision loss. The authors show that
this bias is eliminated with the use of their approach.We apply Basu andMan-
ning’s new methodology to compare the effects of percutaneous coronary
intervention (PCI) versus coronary artery bypass grafting (CABG) on survival
and resource use for elderly patients with symptomatic multivessel coronary
artery disease.
Clinical Context
PCI and CABG are both treatments for coronary artery disease (CAD; block-
ages in the arteries that oxygenate the heart). PCI is performed by interven-
tional cardiologists and involves reopening blocked arteries through the use of
instruments threaded into the heart via catheters inserted in the patient’s arm
or leg. CABG is performed by cardiothoracic surgeons and involves sewing
vessels from elsewhere in the patient’s body onto the heart, allowing blood to
bypass the blocked coronary arteries. PCI is less invasive than CABG and is
increasingly the CAD procedure elderly patients receive (Sheridan et al.
2008). A systematic review of PCI versus CABG on survival from random-
ized trials published between 1996 and 2006 found similar overall survival
after 1 and 5 years postrevascularization (Bravata et al. 2007). However,
elderly patients were routinely excluded from many studies listed in the
review, and results from recent randomized trials and observational studies
suggest that among elderly patients with complex multivessel coronary dis-
ease, CABG provides a survival benefit over PCI (Sheridan et al. 2010;
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Kappetein et al. 2011;Weintraub et al. 2012). For this reason, a comparison of
resource use between PCI and CABG must consider the possibility of differ-
ential survival between the two procedures.
We use an innovative approach to determine how PCI differentially
affects institutional days and resource use compared to CABG through
decomposed survival and intensity effects. Specifically, we assess the effects of
PCI versus CABG on survival, institutional (hospital or long-term care) days,
andMedicare payments for up to 6 years of follow-up for a national sample of
elderly Medicare beneficiaries treated with multivessel coronary revasculari-
zation.
METHODS
Data and Cohort Identification
Medicare Provider Analysis and Review (MedPAR) records were used to
identify fee-for-service Medicare beneficiaries aged 66 and older admitted
between January 1, 2003 and October 14, 2004 for symptomatic CAD,
defined by the presence of International Classification of Diseases, Ninth Edition,
Clinical Modification (ICD-9) diagnosis codes 410.xx, 411.1, and 413.9. Each
patient’s first such hospitalization during 2003 or 2004 was considered his
“index admission.” For identified patients, we obtained all MedPAR, Carrier
(Physician), and Outpatient Medicare claims as well as the Medicare Denomi-
nator file for calendar years 2002 through 2008, providing up to 6 years of fol-
low-up information as well as 12 months of claims prior to the index
admission. Patients were excluded if they were admitted for symptomatic
CAD, cardiac surgery, or PCI in the 12 months prior to the index admission.
Patients were also excluded from the analytic sample if they opted out of
Medicare Part A or B or enrolled in a Medicare Advantage plan at any time
between 2002 and 2008.
MedPAR and Carrier records were used to determine whether remain-
ing patients received coronary revascularization during the 30 days following
their index admission date based on claim codes (ICD-9 procedure codes,
Healthcare Common Procedure Coding System codes, or Diagnosis-Related
Group). Patients were included if their initial coronary revascularization pro-
cedure was a multivessel PCI or CABG procedure. We also included patients
who received a staged PCI procedure by including those patients who
received a second PCI procedure within 30 days of an initial single-vessel
PCI. Additional detail of the cohort selection methodology has been
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published previously (Sheridan et al. 2010); a notable difference from the cur-
rent analysis is that the previous work was limited to patients aged 85 and older.
Outcomes and Covariates
We estimated the association between treatment with PCI or CABG and sub-
sequent survival and resource utilization, measured as days in institutional set-
tings (hospitals and long-term care) and Medicare payments. Mortality data
were obtained from the Denominator file. Hospital and skilled nursing facility
(SNF) days paid by Medicare came from MedPAR records. Other long-term
care days paid by other sources (e.g., private pay or Medicaid) were estimated
by identifying physician visits to nursing homes (Iwashyna 2003; Zuckerman
et al. 2007). Medicare payments were obtained from MedPAR, Outpatient,
and Carrier claims.
Covariates included inadjustedmodels includedclinical indicators, patient
socioeconomic status, and hospital characteristics. Cardiac diagnoses identified
during the patient’s index and/or revascularization-related hospitalization(s)
were included from the claims files. Gender and race were obtained from the
Denominator file. Patient ZIP code-level median household income data were
obtained from the 2000 United States Census; a measure of rural/urban status
was obtained by linking patient ZIP code to Rural-Urban Commuting Areas
(Hart, Larson, and Lishner 2005). The 2003 Medicare Provider of Service file
was used to determine hospital characteristics, including ownership type and
medical school affiliation.Clinical comorbiditiesweremeasured by applying the
Healthcare Cost and Utilization Project’s comorbidity criteria to all claims data
for the12 monthsprior to the indexadmission (Elixhauseret al.1998).These cri-
teria normally require that comorbidities be unrelated to a claim’s principal diag-
nosis; we relaxed this assumption to allow for the inclusion of all comorbidities.
To account for potential coding errors, comorbidities onOutpatient and Carrier
claims were only included if the corresponding codes appeared on at least two
claimsgreater than30 days apart (Klabundeet al. 2000).
Analytic Method
The estimator proposed by Basu and Manning (2010) first requires construc-
tion of a dataset with observations at the person-period level. We selected a
period length of 30 days. In addition to including an indicator of treatment
choice (T), all other covariates (X), and the measure of resources consumed
during each period (Y), several specific variables are needed to implement the
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estimators. First, we included a binary indicator (D) of whether the patient died
within the period. Second, if the patient died within a given period, we include
the length of time within the period the patient survived (U; e.g., between 1 and
30 days for a period length of 30 days). Third, we include a binary indicator (C)
of whether the patient was censored at any point before the end of the period or
died in a previous period. The dataset must be constructed to include a
person-period record for all patients for all time periods (i.e., even after death or
censoring).
Estimation of the model results in an incremental effect of the treatment
variable of interest on resource use, decomposed into that due to survival and
that due to intensity. Here, we describe the model in less technical language;
for complete details of the model derivation, the reader should consult Basu
and Manning (2010). This estimation involves four steps: (1) for each patient-
period in which the patient was alive and not censored at the beginning of the
period, calculate the predicted probability of survival to the start of the period
and a hazard function for death during the period, as well as the associated
incremental effects of the treatment variable; (2) for each patient-period in
which the patient died, calculate the predicted resource use for the period and
the associated incremental effect of the treatment variable; (3) for each patient-
period in which the patient was alive and not censored at the beginning of the
period, calculate the predicted resource use and the associated incremental
effect of the treatment variable; and (4) combine these estimates for all patients
and all periods to calculate the incremental effect of the treatment variable on
overall resource use, decomposed into the survival effect and the intensity
effect.
For each step, we provide general directions as well as details regarding
our implementation:
1. Using the patient-period observations in which the patient was not
censored at any point during the period and was alive at the begin-
ning of the period (i.e.,C = 0), estimate a survival model as a function
of treatment choice and covariates. Relying on estimated coefficients
from the survival model, calculate the predicted probability of sur-
vival until the start of the period (S(T,X)) and the hazard function for
death during the period (h(T, X)) for each patient-period observation.
In addition to estimating the predicted probabilities, estimate the
incremental effect of the treatment variable on both S and h (DS/DT
and Dh/DT, respectively). In our implementation, we calculated all
incremental effects using recycled predictions (i.e., after building the
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model, using it to simulate, for all subjects, expected outcomes from
both treatments).
2. Using the patient-period observations in which the patient was
observed to die (i.e., D = 1), estimate a model predicting resource
use as a function of T, X, and U. Incorporating U accounts for vari-
ability in costs due to the timing of death during the period in which
the patient died. For example, if a patient dies on day 2 of a month,
he has fewer days to incur costs than a patient who dies on day 19.
For all patient-period observations, estimate the predicted resource
use (l1(T, X, U)) and the effect of the treatment variable on predicted
resource use (Dl1(T, X, U)/DT)). Of note, U is not available for peri-
ods in which the patient did not die; thus, both predicted resource use
and the treatment effect were obtained by generating multiple predic-
tions for each person-month observation (reflecting the range of val-
ues of U), then taking a weighted average based on the distribution of
U among individuals who did die. To reduce computational complex-
ity, we reduced the number of levels of in U by first dividing into five
discrete levels (e.g., for 30-day intervals, each 6 days long).
3. Using the patient-period observations in which the patient was
observed to live and was not censored (i.e., D = 0 and C = 0), esti-
mate resource use as a function of Tand X. For all patients in all peri-
ods (including periods in which the patient died or was censored), use
the model estimates to predict resource use (l2(T, X )) and the effect
of the treatment variable on predicted resource use (Dl2(T, X )/DT ).
4. Using the within-period effects calculated for each patient in the three
stages outlined above for each period j = 1 through K (the end of the
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The first term in large curly brackets represents the survival effect, while
the second is the intensity effect.
To estimate survival, we applied discrete-time methods using a pooled
logistic regression model. Such an approach involves a modest reduction in
statistical power when compared with continuous time methods such as Cox
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proportional hazard models. However, its advantages are that it is both readily
estimated using the same person-month analytic dataset needed for the remin-
der for the model and easily allows for incorporation of time-varying effects
through interactions between treatment and time indicators. Hazard rates were
approximated using monthly transition probabilities. To estimate resource use
in periods in which individuals died, we used a Poisson model for the institu-
tional days outcomes and applied a generalized linear model with a log link and
gamma distribution for the Medicare payments outcome. Poisson was chosen
rather than negative binomial because the point estimate of regression parame-
ters estimated by Poisson are consistent even with over- or underdispersion of
the response variable (Wooldridge 2010). For observations in which patients
were observed to live throughout the period, we applied two-part models with
logistic regression for the first part; the second part used zero-truncated Poisson
and generalized linear regression with log link and gamma distribution models
for the institutional days and Medicare payment outcomes, respectively. An
exception was made for the first 30-day period (which included the revasculari-
zation procedure); since all patients had inpatient days and expenditures related
to revascularization, one-part models were used in the first period. The Stata
code used to implement themodel is provided in anOnline Appendix.
To allow for a time-varying effect of PCI/CABG on survival and service
use, we specified the effect of treatment using interaction terms between revas-
cularization choice and a linear spline. The linear spline had knots at 2, 3, 4, 5,
6, 12, 24, 36, 48, and 60 months. Confidence intervals were obtained through
bias-corrected bootstrapping techniques using 250 repetitions, with bootstrap
sampling performed clustered at the person level. Inferential statistics were
considered significant at a two-sided alpha level of 0.05. Datasets were con-
structed in SAS System, Version 9.2 (SAS Institute, Cary, NC, USA), and all
statistical calculations were conducted in Stata/IC 12.1 (StataCorp LP,
College Station, TX, USA).
RESULTS
Cohort
The analysis cohort included 102,877 Medicare beneficiaries with symptom-
atic CADwho were treated with PCI or CABG as the initial choice of revascu-
larization therapy for multivessel disease. Of these, 64,727 beneficiaries (62.9
percent) received CABG. When compared with patients receiving PCI
(Table 1), CABG patients were younger and less likely to be female. CABG
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patients were less likely to be receiving state Medicaid buy-in benefits but
lived in ZIP codes with lower median household income. ST-elevation myo-
cardial infarction (STEMI) was less common and non-STEMI more common
among CABG patients. CABG patients were more likely to have a history of
prior stroke and/or have diabetes but less likely to have cancer, congestive
heart failure, or valvular disease. Ownership type of the revascularization
facility did not significantly differ between PCI and CABG, but CABG was
less likely to be performed in a facility with a major medical school affiliation.
Impact of Treatment Choice on Survival
Prior to adjustment for patient and provider characteristics, CABG patients
were observed to have greater short-term mortality within the year following
revascularization when compared with PCI recipients, but they had a growing
survival benefit after the first year (Figure 1A). We integrated the survival
curves with respect to time to calculate life days and took the difference
between CABG and PCI to calculate the incremental difference. Prior to
Table 1: Selected Covariates by Initial Revascularization Procedure
PCI CABG p-value
Number of patients 38,150 64,727
Patient demographics
Age (years) 76.0 74.7 <.001
Female 47.0 36.8 <.001
Nonwhite race 7.2 7.2 .95
ZIP-codemedian household income (1,000s of USD) 43.2 42.4 <.001
State medicaid buy-in 10.5 9.3 <.001
Patient clinical status
ACS diagnosis
ST-elevationmyocardial infarction 23.9 18.3 <.001
Non-ST-elevationmyocardial infarction 26.1 28.1
Angina 50.0 53.6
History of prior stroke 7.2 7.6 .02
Cancer 8.9 7.9 <.001
Congestive heart failure 9.0 5.7 <.001
Diabetes mellitus 31.5 35.0 <.001
Valvular disease 5.2 2.9 <.001
Revascularization facility characteristics
Ownership type
Nonprofit 79.1 79.1 .38
For-profit 11.4 11.6
Government 9.5 9.3
Major medical school affiliation 32.4 30.5 <.001
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Figure 1: Unadjusted Survival, Days Spent in an Institutional Setting, and
Medicare Payments after Revascularization with Percutaneous Coronary
Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)
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adjustment, patients who received CABG lived, on average, 59.1 days longer
than patients receiving PCI at 72 months postrevascularization (Table 2A).
Statistical adjustment for covariates reduced this difference to 23.1 days and
prolonged the time point at which CABG patients began experiencing longer
average survival than PCI; on average, CABG recipients lived fewer life days
than PCI recipients until 42 months following revascularization, after which
the survival benefit associated with CABGover PCI grew rapidly (Figure 2A).
Impact of Treatment Choice on Resource Use
Prior to adjustment, CABG recipients spent more days in institutional settings
than PCI recipients and had higher Medicare payments (Figure 1B and C).
After adjustment, at 72 months postrevascularization, CABG recipients on
average had spent 10.9 more days in institutional settings than PCI recipients
(95 percent CI: [10.1,11.8]) and had total Medicare payments that were
$12,834 higher (95 percent CI: [$12,032, $13,609]; Table 2B and C). The
greater use of institutional days and total Medicare payments associated with
receipt of CABG appeared most strongly associated with the peri-procedural
period, as the effects diminished in magnitude over the follow-up period (Fig-
ure 2B and C). The differences in resource utilization observed between
CABG and PCI were overwhelmingly driven by intensity effects rather than
survival effects (Figure 3A and B); 95.3 percent of the difference in Medicare
payments was due to intensity effects (Table 2B). CABG recipients had higher
institutional days in both acute care and long-term care settings (7.2 and
4.2 days, respectively).
Subgroup Analyses
We performed several adjusted subgroup analyses predicated upon clinically
meaningful subpopulations of the elderly (Table 2C). Relative to PCI, CABG
use was associated with a greater improvement in survival for men than
women (incremental difference: 44.8 days vs 8.1), along with fewer incre-
mental institutional days and lower Medicare payments (9.8 days vs. 12.1 and
$12,562 vs. $12,984, respectively). Similarly, CABG was associated with
greater incremental life days among patients with diabetes, peripheral vascu-
lar disease, and/or congestive heart failure (CHF); however, only CHF
appeared to demonstrate a meaningful difference in resource costs by CHF
status, with CHF patients having greater incremental institutional days and
Medicare payments after CABG versus PCI compared to those without CHF.
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Figure 2: Adjusted Estimates of Incremental Survival and Resource Use
after Revascularization with Percutaneous Coronary Intervention (PCI) ver-
sus Coronary Artery Bypass Grafting (CABG). (Incremental differences are
cumulative from time of the initial revascularization procedure. Vertical bars
indicate 95 percent pointwise confidence intervals, displayed at 2-month inter-
vals for clarity)
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Alternative Models
We performed two alternative analyses to assess the robustness of our findings
to model specification. In the first, we performed propensity score matching
on the sample, and we then used the 73,846 patients for which a match was
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Figure 3: Decomposition of Adjusted Estimates of Incremental Difference
between Coronary Artery Bypass Grafting and Percutaneous Coronary Inter-
vention into Portion Attributable to Differences in the Intensity of Service Use
among Survivors (Intensity Effect) and Portion Attributable to Changes in
Duration of Survival (Survival Effect). (Incremental differences are cumulative
from time of initial revascularization procedure. Vertical bars indicate 95 per-
cent pointwise confidence intervals, displayed at 2-month intervals for clarity)
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on survival and resource use using a series of binary indicators for period (e.g.,
an indicator for month 1, month 2, etc.) rather than the previously described
linear spline. Neither alternative specification altered the findings substan-
tively (Table 2D). Furthermore, although IPWmethods may introduce bias if
survival effects are substantial, we also calculated IPW estimates and found
them similar to the estimates presented due to the limited survival effects
(results not shown; available on request).
DISCUSSION
In this study, we outline the implementation and demonstrate the use of an
econometric method developed by Basu and Manning to estimate the long-
term effects of medical treatments on resource use. Compared with the widely
employed methodology of IPW, the Basu/Manning methodology provides
two principal benefits. First, it allows the analyst to decompose resource use
differences into survival and intensity effects, which provides more detail
about the long-term cost trajectories associated with treatment choices. Sec-
ond, it may avoid biased estimates for those treatments that affect both inten-
sity and survival; bias that may be substantial when analyses are performed
using IPW methods in the setting of highly censored data. However, the
Basu/Manning method is significantly more complex to implement than IPW
and more computationally intensive in large datasets due to the need for boot-
strapping. The bootstrapped Basu/Manning result presented here took sev-
eral weeks to compute on a multiprocessor machine, while the IPWestimates
were completed in minutes; this drawback will be ameliorated over time by
improvements in software and processing power. Despite these disadvantages,
we believe that the potential for bias from IPW means that evaluation for
potential differences in survival must precede any decision to use IPW tomea-
sure cost differences, even if the ability to decompose cost differences into
intensity and survival effects is not of interest. If survival differences are dem-
onstrated, then use of the Basu/Manning approach is the most conservative
approach.
In our application, cumulative survival differences between CABG and
PCI over a 6-year follow-up period were modest (23.1 days), although the tra-
jectory of the prediction suggests that a longer follow-up period would enlarge
this difference. Moreover, net survival benefit of CABG did not begin to occur
until 42 months following revascularization. This survival difference occurred
at the cost of 10.9 additional days spent in an institution (i.e., hospital or
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nursing home) as well as $12,834 in additional Medicare payments. Because
the survival differences were modest, intensity rather than survival effects
accounted for most (95 percent) of the estimated differences in institutional
days and Medicare payments. Application of these methods to other medical
conditions where treatments result in a larger difference in survival would
show a larger portion of the estimated differences being attributable to longer
survival and result in greater bias from the use of the IPW method. Further-
more, the available data were limited to only patients continuously enrolled in
Fee-for-Service Medicare between 2003 and 2008, meaning that the only
source of censoring was the difference in follow-up length caused by patients
entering the sample throughout 2003–2004. Applications with higher rates of
censoring would be expected to derive greater benefit from the Basu/Man-
ning method.
Several limitations render our results illustrative rather than definitive.
In particular, there are concerns about incomplete adjustment for treatment
selection and the fact that PCI and CABG likely exhibit heterogeneous treat-
ment effects. Whether a patient receives PCI or CABG is a complex clinical
decision based on a number of factors such as the extent of coronary lesions,
clinical status, and patient preferences that are not captured in administrative
data but may be associated with differences in outcome. Treatment effect het-
erogeneity is a distinct but related issue. Even within the population of elderly
patients with symptomatic angina, for some patients PCI is unquestionably
considered the best procedure (e.g., those patients who present with STEMI
and receive primary PCI to abort the myocardial infarction), whereas for oth-
ers CABG is the obvious choice (e.g., patients with left main coronary artery
disease). The subgroup analyses performed here further illustrate a possible
strong heterogeneity effect for this clinical question. However, the data are not
sufficiently granular to permit identification of the patient subpopulations with
high clinical uncertainty about whether to provide PCI or CABG. In addition,
the use of Medicare payments as an outcome excludes patient and private
third party payer costs that would be relevant in comparing the economic
implications of PCI versus CABG. Our analysis was also limited by an inabil-
ity to measure outpatient prescription expenditures, as Part D data were not
available before 2006. For these reasons, the differences identified in this study
cannot provide clinical guidance.
While many of the limitations outlined above center on the use of Medi-
care claims data, such data do have several important strengths. Because
Medicare coverage is nearly universal and generally retained for life among
Americans aged 65 and older, it provides a more generalizable cohort and
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more complete longitudinal follow-up data than can typically be obtained
from cohorts enrolled in private insurance plans. These key benefits justify the
continued use of Medicare claims for analyses of those diseases that com-
monly affect older adults. The ability to merge Medicare claims with clinical
registries, such as the Society of Thoracic Surgeons database for CABG and
the CathPCI Registry for PCI, offers a potential mechanism through which
the ability to control for patient selection may be improved while retaining a
broadly generalizable cohort (Hammill et al. 2009; Brennan et al. 2012).Mor-
tality results from such a linkage have recently been reported (Weintraub et al.
2012); future resource use analyses may leverage such merged datasets to pro-
vide additional control for patient selection and evaluate potentially heteroge-
neous treatment effects. Similar matched Medicare-registry data exist for
other disease areas, such as the Surveillance, Epidemiology, and End Results
Registry used in oncology research. Continued availability of claims forMedi-
care beneficiaries enrolling in innovative payment arrangements (e.g.,
accountable care organizations or bundled payments) will facilitate analysis in
the above efforts. Finally, additional work is needed to facilitate robust estima-
tion of resource use effects in settings where censoring is likely informative,
such as is commonly seen in private health insurance in which insurance
enrollment and health may be tightly correlated due to job status or in the case
of enrollment inMedicare Advantage.
Although there are valid concerns about the proper role of cost analyses
in governing medical decision making, treatment choices cannot be made in a
vacuum (Garber and Sox 2010); information on incremental resource differ-
ences between procedures is critical for ensuring effective use of limited health
care dollars. In general, this application and the ensuing results highlight the
importance of considering resource use when evaluating the comparative
effectiveness of two procedures and ultimately when making treatment
choices. The Basu/Manning method provides an important new tool to sup-
port this effort.
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